Bluejay Diagnostics Inc (BJDX)

[$treet $inatra]

$BJDX looks to be Bullish again

[$treet $inatra]

Happy New Year my friend! $BJDX news overdue about their De Novo FDA Application

https://ir.bluejaydx.com/news-releases/news-release-details/bluejay-reports-fda-agrees-consider-its-plan-pursue-de-novo-0

[ZipCash]

Happy new year my friend ! All good as well by God's grace, will check out bjdx

[TheFinalCD]

needs way more volume to catch attention imo

[photonspeeder]

$BJDX .94 weekly close on Friday sets it up for a run

[$treet $inatra]

https://www.tickerreport.com/banking-finance/9741516/bluejay-diagnostics-nasdaqbjdx-and-gbs-nysegbs-head-to-head-review.html

[$treet $inatra]

$10 target, I can wait around for that

https://stockcharts.com/c-sc/sc?s=BJDX&p=W&yr=1&mn=3&dy=23&i=p95281460187&r=2894

[crudeoil24]

Valuation: We project our model out to 2030. We apply a conservative 30% success probability to our projected revenues in our Symphony product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models, which are then equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of $10.0

[$treet $inatra]

it will come

Q4 2022 FDA Application Submission!!!

[crudeoil24]

Nice! This equity has no volume! Good luck!

[$treet $inatra]

$BJDX back at its lows, should have a nice upside from here imo

https://stockcharts.com/c-sc/sc?s=BJDX&p=W&yr=1&mn=3&dy=23&i=p95281460187&r=2894

https://bluejaydx.com

Bluejay Diagnostics, Inc. Hosted Key Opinion Leader Event on IL-6 Testing in Critical Care Settings:
The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

[saj]

Nice news moving up

[$treet $inatra]

insiders buying now! https://www.otcmarkets.com/filing/html?id=15615153&guid=_uHwkHAwPHbMdth

[tw0122]

IPO was $10. I’ll be happy with move back to $5-$6

[Stockexpertpro]

BJDX Tiny Float 10$ Upgrade out with 10$ Price target done traded over 50% of the Float this morning in premarket This one could get halted on the CB today to the upside

[conix]

Dawson James - Bluejay Diagnostics (BJDX)

A Rapid Point of Care Test for Sepsis Triage: Razors & Blades - Launching with a Buy Rating and a $10.0 Price Target

Bluejay Diagnostics is focused on improving patient outcomes in the critical care setting using the company’s Symphony diagnostic platform. The goal is to deliver a rapid, cost-efficient, point of care product for IL-6 (a key inflammation marker) in diseases like Sepsis and even Covid, too, in an easy, cost-effective, and rapid manner. In doing so, we see Symphony as driving a paradigm shift.
.
Click here for the full report

A Paradigm Shift – A Rapid Point of Care Test for IL-6: Bluejay’s IL-6 test for sepsis triage is intended to measure IL-6 levels in whole blood samples in near-patient settings. Interleukin-6 (IL-6) is an established biomarker of immune system activation. It is elevated in infection, inflammation, and cancer. IL-6 presents as an early “first responder” and needs to be measured quickly and reliably.

What is Symphony? Symphony is an automated diagnostic system consisting of a fluorescence immuno-analyzer that uses a single-use diagnostic test cartridge with reagents integrated into the cartridge. Symphony utilizes a ‘sample-to-result’ format, which means that once a specimen is taken from the patient, it is placed in the cartridge. Then the cartridge is placed inside the analyzer, where the test is run in minutes without further technician intervention or additional reagent.

Initial Testing Program and Planned Commercialization. This month the Company expects to have a pre-submission filing. Bluejay initiated the start of the clinical testing program for the IL-6 test for sepsis triage in October 2021 under a single protocol at three sites, two sites in the University of Texas Southwestern Medical Center (the William P. Clements Jr. University Hospital and the Zale Lipshy Pavilion Hospital) and the third site at the Parkland Memorial Hospital. Results from this program should form the basis of the FDA Pre-Submission application expected to be filed early this year. The results from this program form the basis of the Company’s planned 510(k) marketing application, intended to be filed in Q322. The Company plans to incorporate feedback from the FDA pre-submission to modify these studies to support premarket clearance (which could be through a traditional 510(k) or de novo application). The Company may also consider alternative regulatory paths, including, for example, an Emergency Use Authorization (EUA).

A Successful IPO – $21.6M (upsized) Funds Raised – Funded through next series of key events. Cash on hand is critical at this stage for both the development and commercialization plans. While we anticipate no immediate need for capital, we do model a future raise to execute the “water-fall” commercial sales strategy in the future.

Valuation: We project our model out to 2030. We apply a conservative 30% success probability to our projected revenues in our Symphony product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models, which are then equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of $10.0

Risks to our thesis include: 1. Regulatory Approvals; 2. Clinical Science 3. Dependence on OEM suppliers; 4. Development of the target markets 5. Intellectual Capital 6. Dilutio

[Afterhoursearnings3]

Buying like mad today

[Afterhoursearnings3]

Getting in here tomorrow, looks promising

[glens0]

Yes I bought in today. OS 12.69Mil

[Eagle1]

Nice

[glens0]

$BJDX Tweet "Close to The explosionRocket
Indications are now fully prepared, the chart is very good looking &ready to breaking the$3.75 barrier &then $4.72 &then to$6.25 &then explosion Like launching some stocks in the last period, if he run very strong we will see price from2number"

$BJDX Close to The explosionRocket
Indications are now fully prepared, the chart is very good looking &ready to breaking the$3.75 barrier &then $4.72 &then to$6.25 &then explosion Like launching some stocks in the last period, if he run very strong we will see price from2number🚀 pic.twitter.com/mSEJu9EEZX

— MR.Hassan ELBradie📈 (@HElbradie) December 13, 2021

[Sage7243]

Easy money here!

[TheFinalCD]

recent $10 IPO, with $7 warrants thats been beaten down to 52w low $2.22 today

BJDX

[Eagle1]

What do we have here?

[crudeoil24]

12M > OS.

BJDX

[crudeoil24]

Recent IPO on 11/10/21 > Nasdaq.

[crudeoil24]

Bluejay Diagnostics, Inc. is an in-vitro diagnostic company. The Company is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The Company offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. It focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The Company's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. It is utilizing the platform for detection of sepsis, cancer and other diseases. It is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.